Management of common bacterial infections of the skin

Current Opinion in Infectious Diseases

Volumn 21, Issue 2, 2008, Pages 122-128

  Bernard, Philippe ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Cellulitis; Erysipelas; Folliculitis; Furunculosis; Impetigo; Skin abscess

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BACITRACIN; BENZATHINE PENICILLIN; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFAZOLIN; CEPHALOSPORIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; FUSIDIC ACID; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; NEOMYCIN; OXACILLIN; PENICILLIN G; PENICILLIN V; PLACEBO; PRISTINAMYCIN; PSEUDOMONIC ACID; RETAPAMULIN; RIFAMPICIN;

AEROMONAS HYDROPHILA; BACTERIAL SKIN DISEASE; BETA HEMOLYTIC STREPTOCOCCUS; CELLULITIS; CLINICAL TRIAL; EPIDEMIC; ERYSIPELAS; FOLLICULITIS; FURUNCULOSIS; GEOGRAPHY; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; IMPETIGO; INCIDENCE; INTERTRIGO; LOW DRUG DOSE; LYMPHEDEMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTPATIENT CARE; PASTEURELLA MULTOCIDA; REVIEW; RISK FACTOR; SKIN ABSCESS; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; VIBRIO;

ANTI-BACTERIAL AGENTS; CELLULITIS; COMMUNITY-ACQUIRED INFECTIONS; ERYSIPELAS; FURUNCULOSIS; HUMANS; IMPETIGO; METHICILLIN RESISTANCE; RISK FACTORS; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 43149111779     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282f44c63     Document Type: Review

References (46)

1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the management of skin and soft tissue infections. Clin Infect Dis 2005; 41:1373-1406.
2. French Society of Dermatology. Consensus conference: management of erysipelas and necrotizing fasciitis. Ann Dermatol Venereol 2001; 128:463-482.
3. Heng MC, Khoo M, Cooperman A, Fallon-Friedlander S. Haemorragic cellulitis: a syndrome associated with tumour necrosis factor-alpha. Br J Dermatol 1994; 130:65-74.
4. Koning S, Mohammedamin RS, Van der Wouden JC, et al. Impetigo: incidence and treatment in Dutch general practice in 1987 and 2001 - results from two national surveys. Br J Dermatol 2006; 154:239-243.
5. Elliot AJ, Cross KW, Smith GE, et al. The association between impetigo, insect bites and air temperature: a retrospective 5-year study (1999-2003) using morbidity data collected from a sentinel general practice network database. Fam Pract 2006; 23:490-496.
6. Rortveit S, Rortveit G. Impetigo in epidemic and nonepidemic phases: an incidence study over 4(1/2) years in a general population. Br J Dermatol 2007; 157:100-105.
7. Goettsch WG, Bouwes Bavinck JN, Herings RMC. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol 2006; 20:834-839.
8. McNamara DR, Tleyieh IM, Berbari EF, et al. Incidence of lower-extremity cellulitis: a population-based study in Olmsted county, Minnesota. Mayo Clin Proc 2007; 82:817-821.
9. Bartholomeeusen S, Vandenbroucke J, Truyers C, Butinx F. Epidemiology and comorbidity of erysipelas in primary care. Dermatology 2007; 215:118-122.
10. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. Br Med J 1999; 318:1591-1594.
11. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006; 155:947-950.
12. Peralta G, Padron E, Roiz MP, et al. Risk factors for bacteremia in patients with limb cellulitis. Eur J Clin Microbiol Infect Dis 2006; 25:619-626.
13. Wiese-Posselt M, Heuck D, Draeger A, et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonisation, 2002-2005. Clin Infect Dis 2007; 44:e88-e95. This well-designed study described the bacteriological characteristics of a furunculosis outbreak due to MSSA in a German village and the success of the long-term efficacy of stringent MSSA decolonization measures in affected patients and their families.
14. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005; 5:275-286.
15. Hota B, Ellenbogen C, Hayden BK, et al. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission? Arch Intern Med 2007; 167:1026-1033.
16. O'Neill AJ, Larsen AR, Skov M, et al. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 2007; 45:1505-1510.
17. Lin JJ, Wu CT, Hsia SH, Chiu CH. Bullous impetigo: a rare presentation in fulminant streptococcal toxic shock syndrome. Pediatr Emerg Care 2007; 23:318-320.
18. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-674.
19. Durupt F, Mayor L, Bes M, et al. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J Dermatol 2007; 157:1161-1167. This prospective bacteriological French study reports a low rate (6%) of MRSA in the community, and suggests that both bullous and nonbullous impetigo are associated with exfoliative toxin.
20. Bernard P, Jarlier V, Santerre-Henriksen A. Antibiotic susceptibility of Staphylococcus aureus strains responsible for cutaneous infections in the community. Ann Dermatol Venerol (in press).
21. Bernard P, Bedane C, Mounier M, et al. Streptococcal cause of erysipelas and cellulitis in adults: a microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989; 125:779-782.
22. Krasagakis K, Samonis G, Maniatakis P, et al. Bullous erysipelas: clinical presentation, staphylococcal involvement and methicillin resistance. Dermatology 2006; 212:31-35.
23. Hasty MB, Klasner A, Kness S, et al. Cutaneous community-associated methicillin-resistant Staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med 2007; 14:35-40.
24. Johnson PN, Rapp RP, Nelson CT, et al. Characterization of community-acquired Staphylococcus aureus infections in children. Ann Pharmacother 2007; 41:1361-1367.
25. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57:7-13. This large antimicrobial surveillance program (1998-2004) monitoring skin and subcutaneous tissue infections confirms that S. aureus is the major organism isolated from furuncles and superficial abscesses in all studied geographic areas.
26. LeBlanc DM, Reece EM, Horton JB, et al. Increasing incidence of methicillin-resistant Staphylococcus aureus in hand infections: a 3-year county hospital experience. Plast Reconstr Surg 2007; 119:935-940.
27. Bahrain M, Vasiliades M, Wolff M, Younus F. Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections. Scand J Infect Dis 2006; 38:702-707.
28. Koning S, Verhagen AP, Van Suijlekom-Smit LW, et al. Interventions for impetigo. Cochrane Database Syst Rev 2004; 2:CD003261.
29. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007; 215:331-340. First published study evaluating topical retapamulin (which belongs to the pleuromutilin class) in impetigo, showing a comparable clinical efficacy with fusidic acid in a noninferiority, phase III clinical trial.
30. Koning S, Van Suijlekom-Smit LW, Nouwen JL, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. Br Med J 2002; 324:203-206.
31. Luby SP, Agboatwalla M, Feikin DR, et al. Effect of handwashing on child health: a randomised controlled trial. Lancet 2005; 366:225-233.
32. Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14:15-19.
33. Szumowski JD, Cohen DE, Kanaya F, et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51:423-428.
34. Mashhood AA, Shaikh ZI, Qureshi SM, Malik SM. Efficacy of rifampicin in eradication of carrier state of Staphylococcus aureus in anterior nares with recurrent furunculosis. J Coll Physicians Surg Pak 2006; 16:396-399.
35. Aminzadeh A, Demircay Z, Ocak K, et al. Prevention of chronic furunculosis with low-dose azithromycin. J Dermatolog Treat 2007; 18:105-108.
36. Gabillot-Carre M, Roujeau JC. Acute bacterial skin infections and cellulitis. Curr Opin Infect Dis 2007; 20:118-123.
37. Koster JB, Kullberg BJ, Van der Meer JW, et al. Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies. Neth J Med 2007; 65:89-94.
38. Leclerc S, Teixeira A, Mahé E, et al. Recurrent erysipelas: 47 cases. Dermatology 2007; 214:52-57. Descriptive study of patients with recurrent erysipelas evaluating prophylaxis efficacy: after 2 years of antibiotic prophylaxis, 72% of patients were recurrence-free.
39. McNamara DR, Tleyjeh IM, Berbari EF, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007; 167:709-715. Retrospective, population-based cohort study describing a predictive model for the recurrence of lower extremity cellulitis with further potential interventions to diminish the proclivity for recurrence in high-risk patients.
40. Phillips S, MacDougall C, Holdford DA, et al. Analysis of empiric antimicrobial strategies for cellulitis in the era of methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007; 41:13-20.
41. Kopp M, Bernard P, Schmit JL. Dealing with bacterial hypodermal infection in general practice: an inquiry and a prospective study. Ann Dermatol Venereol 2001; 128:338-344.
42. Corwin P, Toop L, McGeoch G, et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. Br Med J 2005; 330:129-135.
43. Donald M, Marlow M, Swinburn E, Wu M. Emergency department management of home intravenous antibiotic therapy for cellulitis. Emerg Med 2005; 22:715-717.
44. Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669-1674.
45. Bernard P, Chosidow O, Vaillant L. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adult patients: randomised, noninferiority, open trial. Br Med J 2002; 325:864-866.
46. Vignes S, Dupuy A. Recurrence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. J Eur Acad Dermatol 2006; 20:818-822.